Patients with GCA receiving combination IVMP/MTX with lower-dose prednisone had lower cumulative GC doses and fewer related side effects vs SOC.

- First subject received unilateral administration of NRTX-1001 in a new non-MTS cohort; no significant surgical complications or adverse events reported to date - - Data from this non-MTS cohort, ...

(RTTNews) - AbbVie Inc. (ABBV), Wednesday announced Health Canada has issued a Notice of Compliance for RINVOQ for the treatment of adults with giant cell arteritis, both used in combination with a ...

The most dramatic symptoms of GCA (for example, visual loss) result directly from the inflammation of the large- and medium-sized cranial vessels. Other symptoms appear nonspecific and are related to ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according to findings from a team at the Perelman School of ...

5. Positive temporal artery biopsy Biopsy specimen with the artery showing vasculitis characterized by prominence of mononuclear cell infiltration or granulocyte inflammation, often with ...

Please provide your email address to receive an email when new articles are posted on . At the Congress on Controversies in Ophthalmology, Lee and Susan Mollan, MBChB, FRCOphth, PhD, debated this ...

Findings showed 46.4% of patients treated with upadacitinib 15 mg achieved sustained remission compared with 29.0% of those who received placebo. The Food and Drug Administration (FDA) has approved ...

NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib), 15 mg, once daily, for the ...